Cxbladder® Monitor
Non-invasive bladder cancer surveillance — reduce cystoscopy burden in NMIBC
Cxbladder® Monitor is a urine genomic test designed for patients with non-muscle invasive bladder cancer (NMIBC) who require surveillance monitoring for recurrence. It offers a non-invasive alternative that can reduce the burden of repeated cystoscopy. In suitable patients with sustained negative results, Monitor can replace cystoscopy in the long term following shared decision-making between clinician and patient.
Patients undergoing surveillance for recurrent non-muscle invasive bladder cancer (NMIBC) who require regular monitoring. Can alternate with cystoscopy to reduce the frequency of invasive surveillance, or replace cystoscopy in low-risk patients with consistently negative results.
Not for first-line diagnosis of bladder cancer. Not for high-grade or muscle-invasive bladder cancer surveillance without cystoscopy. Not a replacement for cystoscopy where clinical concern is present.
| Step / Test | Accuracy | Notes |
|---|---|---|
| NPV | 97% | |
| Sensitivity | 93% |
Urine in Cxbladder container
30–50 mL midstream urine collected into the Cxbladder collection tube (contains preservative). Do not use catheter samples.
- First void urine (Only 2nd pass of the day or later is accepted)
- Grossly bloody urine
- Acute UTI (Treat UTI first and delay test for 2 weeks)
- <2 weeks after cystoscopy
- <6 weeks after BCG
Available through Codex Genetics as the authorised Pacific Edge distributor in Hong Kong.
Cxbladder specimens must be collected using the dedicated Cxbladder collection kit.
- Request a collection kit from your healthcare provider or Codex Genetics.
- Collect midstream urine (30–50 mL) into the provided tube with preservative.
- Seal securely; store at room temperature.
- Deliver to Codex Genetics Laboratory within 5 days of collection. Address: Unit 220, 2/F, Building 16W, HKSTP, Pak Shek Kok, NT, Hong Kong.
Please contact us for pricing.
- Cxbladder Monitor Score < 3.5
- Low probability of recurrent urothelial carcinoma
- Cxbladder Monitor Score >= 3.5
- Cannot rule out urothelial carcinoma and a clinician-directed protocol to determine if recurrent Urothelial Carcinoma is present is warranted
NMIBC accounts for ~75% of bladder cancer cases. Standard surveillance requires regular cystoscopy, which is invasive, costly, and burdensome for patients. Published clinical studies show Cxbladder Monitor has high sensitivity for detecting recurrence, enabling clinicians to alternate with or substitute cystoscopy in appropriate patients.
Hong Kong-based molecular diagnostics laboratory specialising in clinical genomics, precision oncology, and rare disease diagnosis. Accredited to ISO 27001 and GenQA standards.
© 2026 Codex Genetics Limited. All rights reserved.
